Background
Methods
Patients and tumour specimens
Immunohistology
Antigen | m/p | Clone | Species | Company | Secondary antibody | Company | Substrate | Antigen retrieval |
---|---|---|---|---|---|---|---|---|
CD68 | m | PG-M1 | Mouse | Agilent | anti-mouse-Ig/ peroxidase | Vector | DAB | Tris/EDTA pH 9.0 |
CD163 | m | 10D6 | Mouse | Leica Biosystems, Newcastle Upon Tyne, UK | anti-mouse-Ig/ peroxidase | Vector | DAB | 10 mM citrate, pH 5.5 |
Density quantification of cellular infiltrates
Statistical analysis
Results
Variable | Value (%) |
---|---|
No. of patients | 58 |
Gender | |
Female | 13 (22.4%) |
Male | 45 (77.6%) |
Patient age (years) | |
≤ 60 | 21 (36.2%) |
> 60 | 37 (63.8%) |
Pathologic T stage | |
T1/T2 | 29 (50.0%) |
T3/T4 | 29 (50.0%) |
Pathologic N stage | |
Positive | 11 (19.0%) |
Negative | 47 (81.0%) |
Lymphangiosis carcinomatosa | |
Positive | 17 (29.3%) |
Negative | 41 (70.7%) |
Angioinvasion | |
Positive | 30 (51.7%) |
Negative | 28 (48.3%) |
Multiple tumour nodules | |
With | 13 (22.4%) |
Without | 45 (77.6%) |
Tumor size (mm) | |
≤ 50 | 11 (19.0%) |
> 50 | 47 (81.0%) |
Pathologic R category | |
R0 | 49 (84.5%) |
R1/R2 | 9 (15.5%) |
Histologic differentiation | |
Well | 11 (19.0%) |
Moderate/poor | 47 (81.0%) |
Distant metastases | |
With | 11 (19.0%) |
Without | 47 (81.0%) |
Tumor recurrence | |
With | 23 (39.7%) |
Without | 35 (60.3%) |
Local recurrence | |
With | 17 (29.3%) |
Without | 41 (70.7%) |
Distribution of monocytes/macrophages and tumour-infiltrating lymphocytes in HCC
Variable | CD68+/TIF | CD68−/TIF | p value |
---|---|---|---|
No. of patients | 53 | 5 | |
Patient age, years | 0.324 | ||
≤ 60 | 33 (62.3%) | 4 (80.0%) | |
> 60 | 20 (37.7%) | 1 (20.0%) | |
Gender | 0.430 | ||
Female | 42 (79.2%) | 3 (60.0%) | |
Male | 11 (20.8%) | 2 (40.0%) | |
Local tumour recurrence | 0.583 | ||
Positive | 15 (28.3%) | 2 (40.0%) | |
Negative | 38 (71.7%) | 3 (60.0%) | |
Overall tumour recurrence | 0.050 | ||
Positive | 19 (35.8%) | 4 (80.0%) | |
Negative | 34 (64.2%) | 1 (20.0%) | |
Distant Metastases | 0.209 | ||
Positive | 9 (17.0%) | 2 (40.0%) | |
Negative | 44 (83.0%) | 3 (60.0%) | |
Multiple tumour nodules | 0.035 | ||
Positive | 10 (18.9%) | 2 (40.0%) | |
Negative | 43 (81.1%) | 3 (60.0%) | |
Tumour size (mm) | 0.951 | ||
≤ 50 | 10 (10.0%) | 1 (20.0%) | |
> 50 | 43 (90.0%) | 4 (80.0%) | |
R status | 0.772 | ||
Positive | 8 (15.1%) | 1 (20.0%) | |
Negative | 45 (84.9%) | 4 (80.0%) | |
Angioinvasion | 0.583 | ||
Positive | 25 (47.2%) | 2 (40.0%) | |
Negative | 28 (52.8%) | 3 (60.0%) | |
Lymphangiosis carcinomatosa | 0.583 | ||
Positive | 15 (28.3%) | 2 (40.0%) | |
Negative | 38 (71.8%) | 3 (60.0%) | |
Histologic differentiation | 0.951 | ||
Well | 10 (10.0%) | 1 (20.0%) | |
Moderate/poor | 43 (90.0%) | 4 (80.0%) | |
Pathologic T stage | 0.148 | ||
T1/T2 | 28 (53.8%) | 1 (20.0%) | |
T3/T4 | 24 (46.2%) | 4 (80.0%) | |
Pathologic N stage | 0.658 | ||
Positive | 2 (03.8%) | 0 (00.0%) | |
Negative | 51 (96.2%) | 5 (100.0%) |
Variable | CD163+/TCA | CD163−/TCA | p value |
---|---|---|---|
No. of patients | 42 | 16 | |
Patient age, years | 0.177 | ||
≤ 60 | 13 (31.0%) | 8 (50.0%) | |
> 60 | 29 (69.9%) | 8 (50.0%) | |
Gender | 0.680 | ||
Female | 10 (76.2%) | 3 (18.8%) | |
Male | 32 (23.8%) | 13 (81.2%) | |
Local tumour recurrence | 0.398 | ||
Positive | 11 (26.2%) | 6 (37.5%) | |
Negative | 31 (73.8%) | 10 (62.5%) | |
Overall tumour recurrence | 0.320 | ||
Positive | 15 (35.7%) | 8 (50.0%) | |
Negative | 27 (64.3%) | 8 (50.0%) | |
Distant metastases | 0.469 | ||
Positive | 7 (16.7%) | 4 (25.0%) | |
Negative | 35 (83.3%) | 12 (75.0%) | |
Multiple tumour nodules | 0.016 | ||
Positive | 36 (85.7%) | 9 (56.3%) | |
Negative | 6 (14.3%) | 7 (43.8%) | |
Tumour size (mm) | 0.438 | ||
≤ 50 | 9 (21.4%) | 2 (12.5%) | |
> 50 | 33 (78.6%) | 14 (87.5%) | |
R status | 0.695 | ||
Positive | 35 (15.1%) | 2 (12.5%) | |
Negative | 7 (84.9%) | 14 (87.5%) | |
Angioinvasion | 0.311 | ||
Positive | 20 (47.6%) | 10 (62.5%) | |
Negative | 22 (52.4%) | 6 (37.5%) | |
Lymphangiosis carcinomatosa | 0.656 | ||
Positive | 13 (31.0%) | 4 (25.0%) | |
Negative | 29 (69.0%) | 12 (75.0%) | |
Histologic differentiation | 0.979 | ||
Well | 8 (19.0%) | 3 (18.8%) | |
Moderate/poor | 34 (81.0%) | 13 (81.3%) | |
Pathologic T stage | 0.501 | ||
T1/T2 | 22 (53.7%) | 7 (43.8%) | |
T3/T4 | 19 (46.3%) | 9 (56.3%) | |
Pathologic N stage | 0.470 | ||
Positive | 1 (02.4%) | 1 (06.3%) | |
Negative | 41 (97.6%) | 15 (93.7%) | |
No. of patients | 19 | 39 | |
Lymphangiosis carcinomatosa | 0.035 | ||
Positive | 9 (47.4%) | 8 (20.5%) | |
Negative | 10 (52.6%) | 31 (79.5%) |
Variable | TIL+/TCA | TIL−/TCA | p value |
---|---|---|---|
No. of patients | 20 | 38 | |
Patient age, years | 0.476 | ||
≤ 60 | 6 (30.0%) | 15 (39.1%) | |
> 60 | 14 (70.0%) | 23 (60.9%) | |
Gender | 0.732 | ||
Female | 15 (75.0%) | 30 (78.9%) | |
Male | 5 (25.0%) | 8 (21.1%) | |
Local tumour recurrence | 0.933 | ||
Positive | 6 (30.0%) | 11 (28.9%) | |
Negative | 14 (70.0%) | 27 (71.1%) | |
Overall tumour recurrence | 0.546 | ||
Positive | 9 (45.0%) | 14 (36.8%) | |
Negative | 11 (55.0%) | 24 (63.2%) | |
Metastases | 0.884 | ||
Positive | 4 (20.0%) | 7 (18.4%) | |
Negative | 16 (80.0%) | 31 (81.6%) | |
Multiple tumour nodules | 0.100 | ||
Positive | 18 (90.0%) | 27 (71.1%) | |
Negative | 2 (10.0%) | 11 (28.9%) | |
Tumour size (mm) | 0.206 | ||
≤ 50 | 2 (10.0%) | 9 (23.7%) | |
> 50 | 18 (90.0%) | 29 (76.3%) | |
R status | 0.148 | ||
Positive | 15 (75.0%) | 34 (89.5%) | |
Negative | 5 (25.0%) | 4 (10.5%) | |
Angioinvasion | 0.717 | ||
Positive | 11 (55.0%) | 19 (50.0%) | |
Negative | 9 (45.0%) | 19 (50.0%) | |
Lymphangiosis carcinomatosa | 0.057 | ||
Positive | 9 (45.0%) | 30 (78.9%) | |
Negative | 11 (45.0%) | 8 (21.1%) | |
Histologic differentiation | 0.576 | ||
Well | 3 (15.0%) | 8 (21.1%) | |
Moderate/poor | 17 (85.0%) | 30 (78.9%) | |
Pathologic T stage | 0.708 | ||
T1/T2 | 9 (47.4%) | 20 (52.6%) | |
T3/T4 | 10 (52.6%) | 18 (47.4%) | |
Pathologic N stage | 0.296 | ||
Positive | 0 (00.0%) | 2 (5.3%) | |
Negative | 20 (100.0%) | 36 (94.7%) | |
CD68+ TAMs/TCA | 0.008 | ||
Positive | 20 (100.0%) | 11 (28.9%) | |
Negative | 0 (00.0%) | 27 (71.1%) |